Smartphone app found to be valid tool in screening for minimal hepatic encephalopathy

September 18, 2013

A smartphone app can quickly screen for cognitive dysfunction often found in patients with cirrhosis, according to a new Virginia Commonwealth University study. The cognitive dysfunction, known as minimal hepatic encephalopathy (MHE), has been difficult to diagnose.

Published in the September issue of the journal Hepatology, the study tested the validity of the Stroop smartphone application – called EncephalApp_Stroop – as a method to screen for MHE.

Validation of the as a health care tool opens the door for its use as a point-of-care (POC) instrument that providers can use to quickly, easily and confidently evaluate their patients who may be suffering from MHE.

"This app can be used to rapidly select which patients are likely to benefit from further MHE testing and potential treatment, which has been lacking at this time." said principal investigator Jasmohan Bajaj, M.D., associate professor, Department of Gastroenterology, Hepatology and Nutrition, VCU School of Medicine, who practices at VCU and McGuire VA Medical Centers. "It can be translated into practice by clinic assistants, nurses or other non-MD professionals to add a cost-effective approach to the rapid diagnosis of MHE."

MHE is associated with impaired quality of life, employment and driving capability and a higher risk of progression to overt hepatic encephalopathy, but treatment has not been standard of care in the U.S. partly because MHE testing is not feasible.

The free EncephalApp_Stroop app, which Bajaj developed, utilizes the Stroop task, which is used to evaluate psychomotor speed and through identification in various combinations of ink colors and words.

To determine the validity of the app as a health care tool, Bajaj and his team recruited 126 patients with , some of whom had overt , 51 age-balanced health controls and 43 additional patients with cirrhosis for the prospective validation cohort. They underwent a battery of recommended cognitive tests including the traditional MHE test and the Stroop app evaluation.

The team concluded that the Stroop app is a valid, reliable method for screening for MHE. Use of the app may improve the screening process by making it easier and faster and, subsequently, increase treatment rates in potential with MHE.

They suggest further studies evaluating the app's validity in other populations are needed.

The app can be downloaded on iTunes for iPhones or iPads and is available in Spanish, Czech, Slovak and Indonesian languages.

Explore further: Detection and treatment for hepatic encephalopathy prevents car accidents, reduces costs

Related Stories

New app from UK researcher helps clinician communications

September 17, 2013

There's an app for that. A new iOS app developed in part by University of Kentucky researcher Elaine Wittenberg-Lyles will assist health care professionals seeking help communicating with patients during difficult conversations.

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.